Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Jan 18, 2024 1:24pm
144 Views
Post# 35834038

RE:RE:RE:RE:RE:RE:What is going on ?

RE:RE:RE:RE:RE:RE:What is going on ?Bellend I am always cuatiously optomistic something good will happen to Replicel even with the disappointing Arbitration ruling.  What is annoying me is we are now past 3 months with no update on what direction Replicel will now take.  That in my mind is not acceptable. How long does it take to work out the "legal" aspect of whatever they are working on ?

Happy to hear that Metzger was in contact with Andrew but instead of something tangible we get the usual vagueness.  Shiseido, Dermal Injector and an update  in "a couple of weeks".

Not sure what may be happening with Shiseido unless possibly they have made an offer to Shiseido to sell the global rights to RCH-01.

With the Dermal Injector it is the same old thing they need to find a North American manufacturer to proceed with acquiring FDA Approval.

We also need to hear what is the status of the parnership with Yofoto.  Is that still active or long gone. 
<< Previous
Bullboard Posts
Next >>